<?xml version='1.0' encoding='utf-8'?>
<document id="24293056"><sentence text="A phase I open-label study to investigate the potential drug-drug interaction between single-dose dacomitinib and steady-state paroxetine in healthy volunteers."><entity charOffset="98-109" id="DDI-PubMed.24293056.s1.e0" text="dacomitinib" /><entity charOffset="127-137" id="DDI-PubMed.24293056.s1.e1" text="paroxetine" /><pair ddi="false" e1="DDI-PubMed.24293056.s1.e0" e2="DDI-PubMed.24293056.s1.e0" /><pair ddi="false" e1="DDI-PubMed.24293056.s1.e0" e2="DDI-PubMed.24293056.s1.e1" /></sentence><sentence text="Dacomitinib is currently in development for the treatment of non-small cell lung cancer"><entity charOffset="0-11" id="DDI-PubMed.24293056.s2.e0" text="Dacomitinib" /></sentence><sentence text=" Formation of the major circulating metabolite (PF-05199265) is mediated by cytochrome P450 (CYP) 2D6 and CYP2C9" /><sentence text=" This phase I, single fixed-sequence, two-period study evaluated the effect of paroxetine, a CYP2D6 inactivator, on dacomitinib pharmacokinetics in healthy volunteers who were extensive CYP2D6 metabolizers"><entity charOffset="79-89" id="DDI-PubMed.24293056.s4.e0" text="paroxetine" /><entity charOffset="116-127" id="DDI-PubMed.24293056.s4.e1" text="dacomitinib" /><pair ddi="false" e1="DDI-PubMed.24293056.s4.e0" e2="DDI-PubMed.24293056.s4.e0" /><pair ddi="false" e1="DDI-PubMed.24293056.s4.e0" e2="DDI-PubMed.24293056.s4.e1" /></sentence><sentence text=" Subjects received a single 45-mg dacomitinib dose alone and in combination with paroxetine (30 mg/day for 10 consecutive days, with dacomitinib administered on day 4) at steady-state levels"><entity charOffset="81-91" id="DDI-PubMed.24293056.s5.e0" text="paroxetine" /><entity charOffset="133-144" id="DDI-PubMed.24293056.s5.e1" text="dacomitinib" /><pair ddi="false" e1="DDI-PubMed.24293056.s5.e0" e2="DDI-PubMed.24293056.s5.e0" /><pair ddi="false" e1="DDI-PubMed.24293056.s5.e0" e2="DDI-PubMed.24293056.s5.e1" /></sentence><sentence text=" Blood samples were collected through 240 hours post-dacomitinib dosing" /><sentence text=" Dacomitinib exposure (area under the concentration-time curve from 0 to infinity; AUCinf) increased 37%; however a reduction in PF-05199265 AUCinf of approximately 90% was observed during the paroxetine treatment period"><entity charOffset="193-203" id="DDI-PubMed.24293056.s7.e0" text="paroxetine" /></sentence><sentence text=" The maximum concentration of dacomitinib changed minimally"><entity charOffset="30-41" id="DDI-PubMed.24293056.s8.e0" text="dacomitinib" /></sentence><sentence text=" Adverse events reported with single-dose dacomitinib administered alone or in the presence of steady-state levels of paroxetine were mostly mild, and no serious adverse events were reported"><entity charOffset="42-53" id="DDI-PubMed.24293056.s9.e0" text="dacomitinib" /><entity charOffset="118-128" id="DDI-PubMed.24293056.s9.e1" text="paroxetine" /><pair ddi="false" e1="DDI-PubMed.24293056.s9.e0" e2="DDI-PubMed.24293056.s9.e0" /><pair ddi="false" e1="DDI-PubMed.24293056.s9.e0" e2="DDI-PubMed.24293056.s9.e1" /></sentence><sentence text=" While paroxetine significantly inhibited CYP2D6-mediated metabolism of a single dose of dacomitinib, the modest effect on dacomitinib exposure is unlikely to be clinically relevant when dacomitinib is given daily"><entity charOffset="7-17" id="DDI-PubMed.24293056.s10.e0" text="paroxetine" /><entity charOffset="89-100" id="DDI-PubMed.24293056.s10.e1" text="dacomitinib" /><entity charOffset="123-134" id="DDI-PubMed.24293056.s10.e2" text="dacomitinib" /><entity charOffset="187-198" id="DDI-PubMed.24293056.s10.e3" text="dacomitinib" /><pair ddi="false" e1="DDI-PubMed.24293056.s10.e0" e2="DDI-PubMed.24293056.s10.e0" /><pair ddi="false" e1="DDI-PubMed.24293056.s10.e0" e2="DDI-PubMed.24293056.s10.e1" /><pair ddi="false" e1="DDI-PubMed.24293056.s10.e0" e2="DDI-PubMed.24293056.s10.e2" /><pair ddi="false" e1="DDI-PubMed.24293056.s10.e0" e2="DDI-PubMed.24293056.s10.e3" /><pair ddi="false" e1="DDI-PubMed.24293056.s10.e1" e2="DDI-PubMed.24293056.s10.e1" /><pair ddi="false" e1="DDI-PubMed.24293056.s10.e1" e2="DDI-PubMed.24293056.s10.e2" /><pair ddi="false" e1="DDI-PubMed.24293056.s10.e1" e2="DDI-PubMed.24293056.s10.e3" /><pair ddi="false" e1="DDI-PubMed.24293056.s10.e2" e2="DDI-PubMed.24293056.s10.e2" /><pair ddi="false" e1="DDI-PubMed.24293056.s10.e2" e2="DDI-PubMed.24293056.s10.e3" /></sentence><sentence text=" Dose adjustment of dacomitinib may therefore not be required upon coadministration with a CYP2D6 inhibitor"><entity charOffset="20-31" id="DDI-PubMed.24293056.s11.e0" text="dacomitinib" /></sentence><sentence text=" " /></document>